Alkylating agents showed no clear difference in relapse at end of therapy (6 to 9 months) compared with cyclosporin (low certainty).
Alkylating agents may leads to lower relapse at 12 to 24 months compared with cyclosporin (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Alkylating agents showed no clear difference in adverse effects: serum creatinine compared with cyclosporin (low certainty).
Alkylating agents may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).
Alkylating agents may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).
It is very uncertain whether alkylating agents changes adverse effects: hypertension compared with cyclosporin (very low certainty).
It is very uncertain whether alkylating agents changes adverse effects: leucopenia compared with cyclosporin (very low certainty).
Alkylating agents probably leads to lower relapse at 6 to 12 months compared with steroids, placebo or both (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Alkylating agents led to higher CPA: leucopenia compared with steroids, placebo or both; GRADE not reported.
Alkylating agents showed no clear difference in chlorambucil: leucopenia compared with steroids, placebo or both; GRADE not reported.